Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932874 | 0.81 | MAPT (0.61) | MAPTNOS3NOS1NOS2TNKS | |
| SCHEMBL16997510 | 0.80 | DAO (0.62) | MAPTNOS3NOS1NOS2DAO | |
| SCHEMBL7191331 | 0.80 | MAPT (0.35) | MAPTNOS3NOS1NOS2TNKS | |
| SCHEMBL20079378 | 0.77 | POLB (0.55) | MAPTNOS3NOS1NOS2TNKS | |
| SCHEMBL13920393 | 0.76 | NFKB1 (0.41) | MAPTL3MBTL1DAOCASP3PGR | |
| SCHEMBL16997517 | 0.76 | MEN1 (0.54) | MAPTL3MBTL1DAOPGR | |
| SCHEMBL16997527 | 0.76 | DAO (0.60) | DAOPGR | |
| SCHEMBL31744065 | 0.76 | L3MBTL1 (0.42) | MAPTL3MBTL1DAOPGR | |
| SCHEMBL639722 | 0.76 | NR1H2 (0.40) | MAPTTNKSL3MBTL1TNKS2 | |
| SCHEMBL7184073 | 0.75 | PGR (0.42) | MAPTNOS3NOS1NOS2TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | MAPT 3408/4885NOS3 818/4885NOS1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.